SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is trending following news of a strategic manufacturing partnership aimed at significantly reducing production costs and expanding capacity, which has driven substantial intraday stock volatility. The community is actively discussing the stock's low float and high trading volume, fueling speculation about a potential short squeeze and anticipating further upward movement as it tests key resistance levels. This partnership is seen as a crucial step for scaling their fingerprint drug screening technology ahead of anticipated future market expansion.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending due to recent discussions surrounding its integration as a fuel-discount token within the EzFill app, generating buzz about its expanding utility. The community is sharply divided, with many anticipating significant future appreciation from multi-year lows and viewing it as "digital silver," while others express frustration over its recent price action and struggle to overcome key resistance levels.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is currently a focal point for year-end tax loss selling, leading to sharp price movements and a polarized community discussion. Many foresee further declines for the meme coin, while a resilient group of long-term holders views the current dip as a strategic accumulation opportunity for future crypto cycles, with eyes on a potential rally in 2026.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending significantly following the FDA approval of NEREUS, marking the first new pharmacologic treatment for motion-induced vomiting in over four decades. The community is actively discussing the drug's potential beyond motion sickness, particularly its vast opportunity in addressing GLP-1 induced nausea, which many see as a transformative revenue driver for the company. With analysts raising price targets and whispers of potential buyout interest, investors anticipate continued upside as the market fully prices in this key regulatory win and the company's robust pipeline.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESH Acquisition Corp (ESHA) is trending within a volatile low-float SPAC sector, fueled by discussions surrounding its extremely tight share float and high insider ownership. The community is actively debating its potential for rapid price movement and a short squeeze, drawing comparisons to other recently surging SPACs as new utility via a planned reward token is also highlighted.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics (CORT) is trending with significant volatility after receiving an FDA Complete Response Letter for its relacorilant drug, triggering a sharp decline in shares. The community is fiercely divided, with many calling the sell-off an overreaction given the company's existing profitable drug and deep pipeline, while others foresee further downside following analyst downgrades and a need for more clinical evidence. This binary regulatory event has intensified speculation, as investors weigh potential recovery against lingering uncertainty.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending following the FDA's acceptance and priority review of AXS-05 for Alzheimer's disease agitation, alongside positive feedback supporting an upcoming NDA for AXS-12 in narcolepsy. The market is reacting strongly to this dual pipeline advancement, with community members expressing high optimism and noting significant short-covering as a key driver of the momentum.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after a competitor's drug for Cushing's syndrome received a regulatory setback from the FDA, which the community views as a significant advantage for Xeris's approved treatment, Recorlev. This development is seen as clearing the path for Recorlev to gain market share, fueling discussions among investors about the company's long-term growth potential and undervaluation, supported by positive analyst outlooks.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is highly active following the CME Group's recent, repeated increases in margin requirements for silver futures, sparking intense debate among traders who see it as a desperate measure to control a surging market. This volatility is further fueled by conflicting narratives around impending Chinese silver export restrictions and the growing disconnect between paper and physical prices. The community is sharply divided between those predicting a massive short squeeze driven by industrial demand and global supply shifts, and those anticipating a significant pullback.

Alchemy Investments Acquisition Corp. 1 is a blank check company, which engages in merger, share exchange, asset acquisition, share purchase, and reorganization or similar business combination. The company was founded on October 27, 2021 and is headquartered in Newark, DE.

Alchemy Investments Acquisition Corp 1 - Ordinary Shares - Class A

ALCY is attracting considerable attention, primarily driven by its status as a low-float SPAC, leading to strong comparisons with other recent tickers that have seen significant, swift price movements. The community is actively discussing "dip buys" and speculating on potential upside, with many anticipating a continuation of the "low float SPAC bubble" trend while also acknowledging the inherent risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Sunshine Biopharma (SBFM) rose 11% on Thursday morning after the company announced that its Canadian unit, Nora Pharma, launched a generic version of Bristol-Myers Squibb’s Pravachol.The drug, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://sunshinebiopharma.com/wp-content/uploads/2025/10/20251016_SBFM_Press-Release_Launches-Pravastatin.pdf">called</a> Pravastatin, is a statin medication that works by lowering bad cholesterol (LDL) and increasing good cholesterol (HDL) in the blood, thereby helping prevent heart attacks, strokes, and other serious cardiovascular conditions.Nora Pharma’s Pravastatin is available in strengths of 10 mg, 20 mg, and 40 mg, and comes in bottles of 100 tablets.Sunshine Biopharma said that the Canadian market of cholesterol-lowering drugs is estimated to reach $582 million by the end of 2025 and $1.07 billion by 2033.Sunshine Biopharma currently has 74 generic prescription drugs on the market in Canada, and more than 12 additional drugs are scheduled to be launched in 2026. The company is also seeking to develop drug candidates in the treatment of liver cancer and coronavirus infections.On Stocktwits, retail sentiment around SBFM stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:589/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_16_at_10_55_53_AM_png_97567a6c3b.webp" alt="SBFM's Sentiment Meter and Message Volume as of 10:55 a.m. ET on Oct. 16, 2025 | Source: Stocktwits" width="589" height="62"><figcaption>SBFM's Sentiment Meter and Message Volume as of 10:55 a.m. ET on Oct. 16, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes the company has a bright future.<stembedurl>https://stocktwits.com/Knowledgeworthmore/message/632572691</stembedurl>Another said that they intend to hold the stock long term.<stembedurl>https://stocktwits.com/BanditKnight47/message/632549060</stembedurl>In July, Sunshine Bioopharma <a href="https://stocktwits.com/news-articles/markets/equity/sunshine-biopharma-stock-soars-after-launch-of-first-biosimilar-in-10-b-canadian-market-retail-bulls-charge-in/chFjax5Rchk">introduced</a> its first biosimilar drug, Niopeg, to the Canadian market, to treat the risk of infection in cancer patients undergoing chemotherapy. In June, a generic version of Neurontin, Gabapentin, was launched for treating neuropathic pain and epilepsy.SBFM stock is down by 29% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-draws-investor-interest-as-european-regulator-reportedly-terms-door-safety-a-priority/ch6p3LDR3nA">Tesla Stock Draws Investor Interest As European Regulator Reportedly Terms Door Safety A Priority</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Sunshine Biopharma Stock Powers Ahead Following Launch Of Generic Cholesterol-Lowering Drug By Canadian Unit

The drug, called Pravastatin, is a statin medication that works by lowering bad cholesterol (LDL) and increasing good cholesterol (HDL) in the blood, thereby helping prevent heart attacks, strokes, and other serious cardiovascular conditions.

Equity

The drug, called Pravastatin, is a statin medication that works by lowering bad cholesterol (LDL) and increasing good cholesterol (HDL) in the blood, thereby helping prevent heart attacks, strokes, and other serious cardiovascular conditions.


Retail chatter around Sunshine Biopharma surged late Wednesday after the company introduced Niopeg, its first biosimilar drug, into the Canadian market,&nbsp;sending its stock soaring by nearly 14% — its best session in over seven months.The treatment, developed by its subsidiary Nora Pharma, is a pegfilgrastim biosimilar to Neulasta, which is commonly used to reduce the risk of infection in cancer patients undergoing chemotherapy.Niopeg is supplied in a 6mg/0.6mL prefilled syringe and is designed for patients with non-myeloid cancers.&nbsp;The company noted that global demand for Neulasta and similar drugs was worth approximately $4.5 billion last year, with expectations that it could rise to $9.2 billion by 2033, driven by increasing cancer cases and wider chemotherapy use.Canada, although a smaller part of the global market, still plays a disproportionately large role in biologics spending, according to a statement released by the company.&nbsp;The company said that Canada’s biologic drug sales totaled approximately $10 billion in 2020, accounting for roughly one-third of all pharmaceutical expenditures. Biosimilars, such as Niopeg, have gained more traction there in recent years, helped by provincial policies that encourage switching from branded biologics.The launch follows last month’s&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sunshine-biopharma-unit-launches-generic-anticonvulsant-in-canada/chlayAARbC6">rollout of a generic version of Gabapentin</a>, a standard treatment for neuropathic pain and epilepsy, now available in 100 mg, 300 mg, and 400 mg doses, packaged in bottles of 500 capsules.Sunshine Biopharma states that it currently has 72 generic drugs on the Canadian market and plans to introduce more before the end of the year. It’s also pursuing drug candidates in areas such as liver cancer and treatments related to the coronavirus.On Stocktwits, retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/SBFM">Sunshine Biopharma</a> was ‘extremely bullish’ amid a 6,200% jump in 24-hour message volume.One user noted that for the first time in a long while, Sunshine Biopharma was holding onto its gains following a news release, calling the chart setup strong and suggesting the stock could be gearing up for a multi-day run.<stembedurl>https://stocktwits.com/Tryitin/message/619793472</stembedurl>Another user pointed to the significance of the product launch into a $10 billion market and expressed confidence that the stock could see substantial upside in the coming days, even speculating about a potential move into double digits.<stembedurl>https://stocktwits.com/Tryitin/message/619760589</stembedurl>The stock has declined 42.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration depicting tumour infiltrating lymphocyte (TIL) therapy for cancer treatment. During TIL therapy, T-cells (blue) that recognise tumour cells (red) are obtained from a patient. | Image source: Getty Images

Sunshine Biopharma Stock Soars After Launch Of First Biosimilar In $10B Canadian Market: Retail Bulls Charge In

The company launched Niopeg, a biosimilar to Neulasta, designed to reduce the risk of infection in chemotherapy patients.

Shares of Sunshine Biopharma Inc. (SBFM) were in the spotlight on Wednesday after the pharmaceutical company <a target="_blank" rel="noopener noreferrer nofollow" href="https://sunshinebiopharma.com/wp-content/uploads/2025/06/20250611_SBFM_Press-Release_Launches-Gabapentine-1.pdf">announced</a> that its Canadian unit, Nora Pharma, has launched a new generic prescription drug, Gabapentin.Gabapentin is an anticonvulsant medication used to treat neuropathic pain and epilepsy, as well as for the treatment of pain caused by various medical conditions by reducing excess excitation of the neural networks in the brain and spinal cord.Nora Pharma’s Gabapentin is available in strengths of 100 mg, 300 mg, and 400 mg and comes in bottles of 500 capsules.According to Sunshine Pharma, Canada represents approximately 1.2% of the global pharmaceutical market for Gabapentin, which was valued at $1.92 billion in 2024. It is projected to reach $3.07 billion, the company said.CEO Steve Slilaty said that the company is attempting to fortify its presence in Canada’s generic drugs market, valued at $9.4 billion. The market is forecasted to nearly double to $19.2 billion by 2032, he added.Sunshine Biopharma currently has 71 generic prescription drugs on the market in Canada, with over 12 additional drugs planned for launch in the remainder of 2025.On Stocktwits, retail sentiment around SBFM jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:631/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_11_at_1_14_32_PM_png_31faf5b9e5.webp" alt="SBFM's Sentiment Meter and Message Volume as of 1:14 p.m. ET on Jun 11, 2025 | Source: Stocktwits" width="631" height="67"><figcaption>SBFM's Sentiment Meter and Message Volume as of 1:14 p.m. ET on Jun 11, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that short sellers will not risk shorting Sunshine owing to its significant institutional ownership, low float, and ‘HUGE potential.’<stembedurl>https://stocktwits.com/LH1975New/message/617532142</stembedurl><a href="https://stocktwits.com/symbol/SBFM">SBFM stock</a> is down by about 46% this year and has wiped out nearly three-quarters of its valuation over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/intelligent-bio-rises-on-partnership-with-smartox/chlaUpbRbCy">Intelligent Bio Rises On Partnership With Smartox To Expand US Market Presence: Retail Hopes The Stock To Hit $2.6</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sunshine Biopharma Unit Launches Generic Anticonvulsant In Canada: Retail Sees ‘Huge Potential’

CEO Steve Slilaty stated that the company is aiming to strengthen its presence in Canada’s generic drugs market, valued at $9.4 billion.

Sunshine Biopharma, Inc.'s stock rose over 3% on Monday, lifting retail investor sentiment, after the company said its Canadian subsidiary had launched a generic version of an oncology drug.Nora Pharma launched Everolimus — a generic version of Novartis’ Afinitor — in the Canadian generic prescription drug market, Sunshine said.&nbsp;The drug is indicated for advanced renal cell carcinoma, breast cancer in certain post-menopausal women, some neuroendocrine tumors and tuberous sclerosis-related brain tumors.&nbsp;Sunshine said Everolimus is available in 2.5 mg, 5 mg and 10 mg strengths in 30-tablet blister packs.The global Everolimus market is valued at $2.5 billion in 2023 and is projected to hit around $4.8 billion by 2032, the company said.&nbsp;The announcement sent message volume on Stocktwits about Sunshine Biopharma soaring over 14,700% in the 24 hours to late Monday, even as the stock slid over 1% in after-hours trading.Sentiment among retail traders flipped to ‘extremely bullish’ from ‘bearish’ a day ago.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/SBFM_sentiment_and_message_volume_as_of_April_21_png_ee65768271.webp" alt="SBFM sentiment and message volume as of April 21.png" width="1318" height="316"><figcaption>SBFM sentiment and message volume as of April 21. | source: Stocktwits</figcaption></figure>One watcher took heart from Everolimus' sales projections and said it "is going to blow someday."<stembedurl>https://stocktwits.com/JdNews/message/612158515</stembedurl>Another user speculated that the company was soon going to form strategic partnerships.<stembedurl>https://stocktwits.com/contra7/message/612209836</stembedurl>Earlier this month, Sunshine reported new preclinical data for its K1.1 mRNA Lipid Nanoparticle product for hepatocellular carcinoma (HCC).&nbsp;Sunshine’s stock, which has a short interest of 6.6% according to Koyfin, has lost over half its value this year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

A person examines financial data on a screen displaying a graph with upward and downward trends, using a pen to trace the line chart. | Representative Image: Getty Images

Sunshine Biopharma Boosts Retail Trader Appeal After Canadian Launch Of Generic Cancer Drug

Its subsidiary launched Everolimus — a generic version of Novartis’ Afinitor — in the Canadian generic prescription drug market.

Sunshine Biopharma, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of oncology and antiviral drugs. It is also involved in the development and commercialization of science-based nutritional supplements. The firm's product includes treatment for Coronavirus infections and anticancer drugs. The company was founded on August 31, 2006 and is headquartered in Fort Lauderdale, FL.

SBFM
Sunshine Biopharma Inc

Feed

News

Sentiment

Fundamentals

Info

Latest SBFM News

SBFMSunshine Biopharma Inc